Cardiolife
Heart Attack to Cardiovascular Life
In order to significantly restore heart function during the chronic phase of myocardial infarction, a cell source with strong tissue healing capabilities and high differentiation efficiency into cardiomyocytes is needed.
Myocardial infarction (MI) can be treated with stem cell treatment using bone marrow mononuclear cells (BM-MNCs), bone marrow mesenchymal stem cells (MSCs), umbilical cord mesenchymal cells, and umbilical cord-derived exosomes.
MSC transplantation is dependent on the mode of delivery; typically, intravenous, intracoronary artery, and intramyocardial injection are used.
Under ideal circumstances, the effectiveness of the stem cells to be employed, the time and mode of administration, the quantity of cells to be provided, the patient’s background, etc., must all be taken into account.
